Zafgen Inc
Change company Symbol lookup
Select an option...
ZFGN Zafgen Inc
OMC Omnicom Group Inc
BANF BancFirst Corp
AMD Advanced Micro Devices Inc
TVIA TerraVia Holdings Inc
LEI Lucas Energy Inc
BAC Bank of America Corp
FSLR First Solar Inc
VAL Valspar Corp
MPA BlackRock MuniYield Pennsylvania Quality Fund

Health Care : Biotechnology | Company profile

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity. Beloranib is in Phase III stage of development for PWS. It is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor, for the treatment of nonalcoholic steatohepatitis (NASH) and abdominal obesity, as well as other second-generation MetAP2 inhibitors for the treatment of severe obesity. It is also evaluating additional MetAP2 inhibitors beyond Beloranib as a development candidate for the treatment of severe obesity in the general population.

Closing Price
Day's Change
-0.05 (-1.46%)
B/A Size
Day's High
Day's Low
10-day average volume:

Upcoming Events

ZFGN fiscal year ends in December
There are no upcoming events for ZFGN

Past Earnings

This page reports .
DateEvent descriptionEarnings per
share actual
estimate range
Previous year's
August 4, 2016Q2 2016 Earnings Release-$0.55-$0.72 to -$0.62-$0.66
May 10, 2016Q1 2016 Earnings Release-$0.65-$0.84 to -$0.62-$0.53
March 9, 2016Q4 2015 Earnings Release-$0.85-$0.99 to -$0.73-$0.48
November 10, 2015Q3 2015 Earnings Release-$0.73-$0.92 to -$0.69-$0.65

Earnings Calendar and Events Data provided by |Terms of Use| © 2016 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by SunGard.

, , , Copyright © 2016. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.